

Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs (end 31 January 2021)

Abatacept [Orencia]	11
Adalimumab [Humira]	10
AdalimumabBiosimilars	109
Apremilast [Otezla]	26 (1 st September to 31 st December 2020)
Baricitinib [Olumiant]	25
Certolizumab [Cimzia]	21
Etanercept [Enbrel]	<5
EtanerceptBiosimilars	67
Filgotinib [Jyseleca]	Not in data
Golimumab [Simponi]	<5
Infliximab [Remicade]	<5
Infliximab Biosimilars	5
Ixekizumab [Taltz]	0
Rituximab [MabThera]	<5
Rituximab Biosimilars	9
Sarilumab [Kevzara]	8
Secukinumab [Cosentyx]	26
Tocilizumab [Ro Actemra]	36
Upadacitinib [Rinvoq]	Not in data
Ustekinumab [Stelara]	<5

Q2. Could you please provide the numbers of patients treated for Ankylosing Spondylitis ONLY in the last 3 months with the following drugs:

Adalimumab [Humira]	<5
AdalimumabBiosimilars	14
Certolizumab [Cimzia]	<5
Etanercept [Enbrel]	0
EtanerceptBiosimilars	11
Golimumab [Simponi]	<5
Infliximab [Remicade]	<5
Infliximab Biosimilars	<5
Ixekizumab [Taltz]	0
Secukinumab [Cosentyx]	10

Less than five replaces the actual data as this could potentially identify individuals and is exempt under section 38(1)(b) of FOISA.